分子杂交技术在乙型肝炎拉米夫定治疗后YMDD变异检测中的应用  

Detection of YMDD mutation by hybridization technology after treatment of hepatitis B by lamivudine

作　　者：钮海莺[1] 徐爱芳[1] 王妙婵[1] 张永乐[1] 

机构地区：[1]杭州市第六人民医院浙江中医药大学附属杭州第六医院检验科,杭州310014

出　　处：《中国卫生检验杂志》2008年第12期2667-2668,共2页Chinese Journal of Health Laboratory Technology

摘　　要：目的:采用分子杂交技术检测乙型肝炎拉米夫定治疗后发生的YMDD变异基因。方法:对100例服用拉米夫定12个月以上的乙型肝炎患者的血清,采用聚合酶链反应后进行分子杂交技术测定YMDD变异情况,同时采用乙肝P区基因测序技术进行结果比较。结果:100例拉米夫定治疗患者血清经分子杂交技术共检出33例YMDD变异,同测序结果吻合率达96.97%,灵敏度达103IU/ml。33例YMDD变异者共有6种不同的变异组合。结论:分子杂交技术检测HB-VYMDD变异具有简单、准确、快速、经济实用等特点,具有很好的临床应用价值。Objective：To use hybridization to detect lamivudine in the treatment of hepatitis B after YMDD mutation of the gene.Methods：On 100 patients taking lamivudine for more than 12 months of serum hepatitis B patients,using polymerase chain reaction after the hybridization of YMDD mutation,while a hepatitis B P gene sequencing technology.Results：Of 100 cases of lamivudine in the treatment of patients with the hybridization were detected 33 cases of YMDD mutation,with the sequencing results anastomosis rate of 96.97%,sensitivity of 103 IU/ml.33 cases of YMDD mutation total of six different combinations of variation.Conclusion：Hybridization to detect HBVYMDD variation is simple,accurate,rapid and practical.

关 键 词：分子杂交 乙型肝炎 拉米夫定耐药 变异 

分 类 号：R512.62[医药卫生—内科学]